Post-effective amendment to a registration statement that is not immediately effective upon filing

Commitments and Contingencies (Details)

v3.4.0.3
Commitments and Contingencies (Details) - USD ($)
12 Months Ended
Aug. 06, 2013
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2011
Commitments and contingencies (Textual)        
Rent expense   $ 107,385 $ 21,600  
2013 Exclusive Agreement [Member]        
Commitments and contingencies (Textual)        
Milestone payment $ 765,000     $ 765,000
License reduced percentage 50.00%     50.00%
Aggregate maintenance fees for first five years       $ 80,000
Aggregate maintenance fees for first three years $ 7,500      
Maintenance fees annually after first five years $ 5,000     $ 50,000
Royalty Percentage 2.00%     2.00%
Minimum royalty expense $ 75,000     $ 75,000
Royalty description The Company is required to pay The Regents royalties ranging from 8% of worldwide sublicense sales of covered products (if the sublicense is entered after commencement of phase II clinical trials to 12% of worldwide sublicense sales (if the sublicense is entered prior to commencement of phase I clinical trials).     The Company is required to pay The Regents royalties ranging from 8% of worldwide sublicense sales of covered products (if the sublicense is entered after commencement of phase II clinical trials to 12% of worldwide sublicense sales (if the sublicense is entered prior to commencement of phase I clinical trials).
License Costs $ 10,000